Water-polluting anxiety drug reduces fish mortality

August 07, 2014

A drug that is commonly used to treat anxiety in humans and which regularly finds its way into surface waters through wastewater effluence has been shown to reduce mortality rates in fish.

The results, which have been published today, 8 August, in IOP Publishing's journal Environmental Research Letters, may have significant implications for existing standard ecotoxicological tests, which predominantly focus on harmful effects of water contaminants and ignore the potential benefits.

By improving the health of an aquatic organism, a certain pharmaceutical drug may alter the balance of species in an environment and have serious, cascading ecological consequences, according to the researchers from Umeå University in Sweden.

Lead author of the paper Dr Jonatan Klaminder, said: "Ecotoxicological tests were designed with traditional toxic contaminants in mind, such as heavy metals and dioxins, which have historically been the major apparent threat against aquatic organisms in surface waters.

"Pharmaceuticals, which are designed to improve health, are a new group of contaminants that do not necessarily fit into the traditional view.

"I think there is a 'bandwagon effect' within the research community where the old test and the traditional view of a contaminant is routinely used without reflection about the conceptual flaw implicit in the methods."

In their study, the researchers retrieved two-year-old Eurasian perch from a lake in Sweden and randomly exposed them to high and low concentrations of Oxazepam.

Oxazepam is a benzodiazepine which is commonly used to treat anxiety and insomnia in humans and regularly contaminates surface waters via treated wastewater effluent. The researchers have previously shown that the drug can increase the activity and boldness of Eurasian perch.

In this study, the low concentration of Oxazepam was below that measured in treated effluent water in Europe.

The researchers also collected eggs, or roe strings, from a separate population of perch and exposed them during the first nine days of embryonic development to three different concentrations of Oxazepam. After hatching, a random group of the fry were collected and analysed.

Results showed that mortality rates were high among hatched fry -- corresponding to mortality rates found among perch fry in natural populations -- and relatively high among the two-year-old perch, but were significantly reduced by Oxazepam exposure in comparison to the control group of fish who were not exposed.

In the hatched fry, mortality was lower in the high concentration treatment than in the control and low concentration treatments. In the two-year-old perch, mortality was lower in both the low and high concentrations compared to the control.

Co-author of the study Tomas Brodin, who was the ecologist in the research team, said: "A therapeutic effect leading to increased survival of one species may generate a proportional increase in mortality of that species' prey, which may have cascading ecological consequences that need consideration.

"A new, conceptual view of ecotoxicological testing should include the possibility that a substance can improve the health of an organism and make individuals affected by contamination more competitive than non-affected individuals."

"Even though our study focused on one single pharmaceutical contaminant, it is possible that similar effects could be induced by exposure to a whole range of pharmaceuticals that find their way into surface waters, such as antibiotics, painkillers, anti-inflammatory drugs, hormones and antidepressants. Our conceptual view of a pollutant has, up until now, blocked us from testing for similar effects at environmentally relevant concentrations."
-end-
From Friday 8 August, this paper can be downloaded from http://iopscience.iop.org/1748-9326/9/8/084003/article

Notes to Editors

Contact

1. For further information, a full draft of the journal paper or contact with one of the researchers, contact IOP Press Officer, Michael Bishop: Tel: 0117 930 1032 E-mail: michael.bishop@iop.org For more information on how to use the embargoed material above, please refer to our embargo policy.

IOP Publishing Journalist Area

2. The IOP Publishing Journalist Area gives journalists access to embargoed press releases, advanced copies of papers, supplementary images and videos. In addition to this, a weekly news digest is uploaded into the Journalist Area every Friday, highlighting a selection of newsworthy papers set to be published in the following week. Login details also give free access to IOPscience, IOP Publishing's journal platform. To apply for a free subscription to this service, please email Michael Bishop, IOP Press Officer, michael.bishop@iop.org, with your name, organisation, address and a preferred username.

The conceptual imperfection of aquatic risk assessment tests: highlighting the need for tests designed to detect therapeutic effects of pharmaceutical contaminants

3. The published version of the paper 'The conceptual imperfection of aquatic risk assessment tests: highlighting the need for tests designed to detect therapeutic effects of pharmaceutical contaminants' (J Klaminder, M Jonsson, J Fick, A Sundelin and T Brodin 2014 Environ. Res. Lett. 9 084003) will be freely available online from Friday 8 August. It will be available at http://iopscience.iop.org/1748-9326/9/8/084003/article

Environmental Research Letters

4. Environmental Research Letters is an open access journal that covers all of environmental science, providing a coherent and integrated approach including research articles, perspectives and editorials.

IOP Publishing

5. IOP Publishing provides publications through which leading-edge scientific research is distributed worldwide. Beyond our traditional journals programme, we make high-value scientific information easily accessible through an ever-evolving portfolio of books, community websites, magazines, conference proceedings and a multitude of electronic services. IOP Publishing is central to the Institute of Physics, a not-for-profit society. Any financial surplus earned by IOP Publishing goes to support science through the activities of the Institute. Go to ioppublishing.org.

Access to Research

6. Access to Research is an initiative through which the UK public can gain free, walk-in access to a wide range of academic articles and research at their local library. This article is freely available through this initiative. For more information, go to http://www.accesstoresearch.org.uk

The Institute of Physics

6. The Institute of Physics is a leading scientific society. We are a charitable organisation with a worldwide membership of more than 50,000, working together to advance physics education, research and application.

We engage with policymakers and the general public to develop awareness and understanding of the value of physics and, through IOP Publishing, we are world leaders in professional scientific communications.

In September 2013, we launched our first fundraising campaign. Our campaign, Opportunity Physics, offers you the chance to support the work that we do.

IOP Publishing

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.